We reviewed the 5 cardiovascular treatments Americans spend the most on.

Four of them address one mechanism.

Only one covers all five.

Over nine months we examined more than 600 peer-reviewed studies on the bestselling cardiovascular supplements in America and the most-prescribed cardiovascular medications. We ranked each one against the five known mechanisms of cardiovascular decline.

Source · 1948 commercial print archive.The original advertisement for warfarin, patented by the Wisconsin Alumni Research Foundation in 1948 as a rodenticide. Reclassified for human prescription in 1954. The active compound has not changed.

If you're over 50 and on a prescription for blood pressure, cholesterol, or a blood thinner, the question worth asking your cardiologist is not whether the prescription is working. The question is what the prescription is not doing.

The disease has been continuing anyway.

Over the last nine months our team reviewed more than 600 peer-reviewed clinical studies on cardiovascular treatment. We examined the bestselling cardiovascular supplements in the United States. We pulled the FDA-approved mechanisms of action for the most-prescribed cardiovascular medications. What follows is the ranking, and the reason every prescription on your shelf is doing less than your cardiologist told you.

Lisinopril lowers blood pressure. That's all it does. Atorvastatin lowers LDL cholesterol. That's all it does. Eliquis prevents new clots from forming. That's all it does. Each one has been doing its one job, quietly, in millions of American medicine cabinets for a decade and longer.

Part One

The five mechanisms your heart actually needs addressed

Heart disease is not one failure. The published literature documents five distinct mechanisms behind cardiovascular decline in adults over 50. Each operates independently. Each accelerates with age. A complete protocol addresses all five. Most prescriptions address one.

Mechanism I

Plaque cleanup. The fibrinolytic system.

Your body runs a continuous cleanup operation inside every artery. Three enzymes — plasmin, tissue plasminogen activator and urokinase — break down the small fibrin deposits that accumulate daily in arterial walls.1 This system fades with age. Production of plasmin drops roughly 60% between ages 50 and 65.2 By the late sixties the cleanup crew is largely absent. The fibrin it can no longer clear is what becomes the plaque that ruptures into the clot that causes the stroke. Researchers have started calling this drop the plasmin cliff.

Mechanism II

Blood pressure regulation

The smooth muscle lining your arteries stiffens with age. Endothelial nitric oxide production fades. Resting pressure rises. ACE inhibitors relax the muscle. They do not address the stiffening process underneath.

Mechanism III

New clot prevention

Platelet aggregation is the body's emergency response to injured blood vessels. In older adults with inflamed arterial linings it forms clots where they aren't needed. Anticoagulants address this one step.

Mechanism IV

Calcium routing

Calcium that should land in your bones increasingly lands in your arterial walls instead. The signal that routes calcium correctly is Vitamin K2, specifically the MK-7 isomer. American diets are clinically deficient in it.3

Mechanism V

Inflammation suppression

Chronic low-grade inflammation is upstream of every other failure. It damages the arterial lining. The damaged lining attracts platelets. Platelets recruit fibrin. Fibrin recruits calcium. The cycle is the disease. C-reactive protein matters more than LDL, and most cardiologists don't measure it.

Five mechanisms. Address one. The other four keep working against you.
The Scorecard

Five treatments, one test

Treatment Reviewed Plaque
Cleanup 		BP
Regulation 		Clot
Prevention 		Calcium
Routing 		Inflammation
No. 1 Corvael · 5-Active Stack NSK-SD 20,000 FU · K2 MK-7 · Berberine · Aged Garlic · Magnesium ✓ ✓ ✓ ✓ ✓
No. 2 Prescription medications Lisinopril · Atorvastatin · Eliquis / Warfarin class X ✓ ✓ X ~
No. 3 Healthletic Nattokinase Standalone 10,800 FU across 2 capsules ~ ~ ~ X X
No. 4 Rosabella Beetroot extract, single-ingredient blood pressure support X ✓ X X X
No. 5 Resilia Single-ingredient, cardiovascular adjacent X X X X ~
✓ Addresses mechanism ~ Partial or sub-clinical X Does not address

The review, one treatment at a time

Corvael · The five-active stack

Of every cardiovascular treatment we reviewed, including four prescription categories and the bestselling supplements on the American market, only one formulation addressed every one of the five documented mechanisms at the dose used in the underlying research.

That product is a five-active stack manufactured under the brand name Corvael, produced by the supplement manufacturer Blissta. The composition is below, broken down by the mechanism each compound addresses.

Mechanism I · Plaque cleanup

Fibrinolytic restoration

The plasmin cliff is the single most under-addressed mechanism in modern cardiology. Corvael addresses it through the highest clinically validated dose of NSK-SD strain nattokinase available in any consumer cardiovascular product we examined.

NSK-SD Nattokinase · 20,000 Fibrinolytic Units

Discovered by Dr Hiroyuki Sumi at the University of Chicago Medical School in 1980. Published in Experientia 43:1110–1111, October 1987, PMID 3478223. Mechanism: direct fibrinolysis of accumulated fibrin in arterial walls, plus inactivation of PAI-1, the brake on the body's natural cleanup system. Confirmed at population scale by the Takayama Study, 29,079 Japanese adults over 16 years, where top-quartile natto consumers showed a 25% reduction in cardiovascular mortality.8,9

Clinical dose · 10,800 FU minimum · Corvael 20,000 FUMechanism II · Blood pressure

Regulation, not suppression

Where most cardiovascular formulas use a single ingredient for blood pressure, Corvael pairs aged garlic extract with magnesium glycinate.

Aged Garlic Extract · 600 mg · 20-month fermentation

Documented therapeutic use traceable to 1876. Modern record: Ried 2020 meta-analysis, 12 trials, 553 hypertensive patients, average systolic reduction 8.3 mmHg and diastolic 5.5 mmHg.10 The 20-month fermentation converts the harsh sulphur compounds of raw garlic into the softer circulatory compounds the body absorbs.

Clinical dose · 600 to 1,200 mg AGE dailyMechanism III · Clot prevention

A support layer, not a drug

Through the synergy of nattokinase's mild platelet effects and aged garlic's documented inhibition of platelet activity, the Corvael stack provides a support layer beneath the platelet pathway. It does not operate at the pharmacological intensity of an anticoagulant. This matters for safe co-administration alongside prescription blood thinners, which must always be discussed with the prescribing physician.

Mechanism IV · Calcium routing

Where the calcium goes

The Rotterdam Study, one of the most cited cardiovascular cohort analyses of the past 25 years, followed 4,807 participants for over a decade. Top-quartile Vitamin K2 consumers experienced roughly 50% less arterial calcification than the bottom quartile.3

Vitamin K2 · MK-7 isomer · 200 mcg

Activates matrix-Gla protein, the body's calcium-routing signal. Routes calcium away from arterial walls, where it contributes to plaque, and toward bone tissue. The MK-7 isomer is the bioactive form, with a half-life of roughly 72 hours against about 1.5 hours for the older MK-4 form.

Clinical dose · 90 to 200 mcg MK-7 dailyMechanism V · Inflammation

Upstream of everything else

Inflammation sits upstream of every other mechanism. Corvael addresses it through two compounds with deep clinical records.

Berberine HCl · 500 mg

First documented in Western medical practice by the Italian physician Arnaldo Cantani in 1876 in diabetic protocols at the Naples school of medicine. Modern record: Yin 2008, 84 patients with type-2 diabetes, CRP and lipid improvements parallel to metformin at the 500 mg twice-daily dose. AMPK pathway activation, NF-κB suppression.

Clinical dose · 500 mg dailyMagnesium Glycinate · 200 mg

The mineral most American adults over 50 are clinically deficient in. Magnesium calms vascular smooth muscle, supports normal blood pressure regulation, and acts as a cofactor for over 300 enzymatic processes. The glycinate form is the most bioavailable and the gentlest on digestion.

Clinical dose · 200 to 400 mg daily

A complete protocol addresses all five mechanisms. Most prescriptions address one. Most supplements address one.

Of the five major treatments we reviewed across nine months and 600 peer-reviewed studies, only Corvael's five-active formulation addressed every documented mechanism at the clinical dose used in the underlying research.

We are not telling any patient to discontinue a prescription medication. Your blood pressure medication is doing what it was designed to do. Your blood thinner is preventing the next clot. The question is what is being done about the other four mechanisms.

Bring this article to your next cardiologist appointment. Ask about fibrinolytic activity, calcium routing and inflammation suppression. Use those exact words.

From our readers

My cardiologist refilled my Eliquis for the fourth time last month and never said a word about what the prescription doesn't address. I brought this to my next visit. He read the whole thing while I waited. He wrote down four things I had never heard of in fourteen years of going to that office.

Patricia M.

I have been on lisinopril for nine years. The cough has been worse this last year. After reading this I asked my doctor what else I should be doing. He paused for a long time before he answered. The conversation that followed was the first real one I have had with him in all nine years.

Frank D.

My father died of a stroke in 2003 at 67. He was on three medications at the time. None of them were addressing what the autopsy report described. I sent this article to my brothers and to our mother.
Daniel R.

I am a retired ER nurse. I worked the stroke ward at our local hospital for thirty-eight years. Until I read this article last month I had never once heard the word fibrinolytic discussed in any continuing-education session I ever attended. I am sixty-eight years old. I am still angry about it.
Diane M.

Citations and sources

  1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78(12):3114–3124.
  2. Yamamoto K, Takeshita K, Saito H. Plasminogen activator inhibitor-1 in aging. Seminars in Thrombosis and Hemostasis. 2014;40(6):652–659.
  3. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. Journal of Nutrition. 2004;134(11):3100–3105.
  4. Bahadoran Z, Mirmiran P, Kabir A, Azizi F, Ghasemi A. The nitrate-independent blood pressure lowering effect of beetroot juice. Advances in Nutrition. 2017;8(6):830–838.
  5. Yılmaz İ. Angiotensin-converting enzyme inhibitor cough: a literature review. Turkish Thoracic Journal. 2019;20(1):36–42.
  6. Henein MY, et al. Coronary artery calcification progression on statin therapy. Atherosclerosis. 2019;291:48–53.
  7. Link KP. The discovery of dicumarol and its sequels. Circulation. 1959;19:97–107.
  8. Sumi H, Hamada H, Tsushima H, Mihara H, Muraki H. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto. Experientia. 1987;43(10):1110–1111. PMID 3478223.
  9. Nagata C, et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults. American Journal of Clinical Nutrition. 2017;105(2):426–431. PMID 27927636.
  10. Ried K. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota. Experimental and Therapeutic Medicine. 2020;19(2):1472–1478.
  11. Chen H, McGowan EM, Ren N, et al. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomarker Insights. 2018;13. Plus Chen 2022 carotid plaque progression study, 1,062 patients, 36% plaque reduction at 12 months.
  12. ConsumerLab independent testing. Nattokinase supplement brand testing, November 2025. Three of eight tested brands failed manufacturer label claim verification.

Corvael · The five-active stack

GMP-certified facility with per-batch third-party testing for purity and heavy metals. Certificates of analysis published per batch and accessible to the public. The full protocol runs in 90-day cycles, and the five-bottle supply covers the complete arc the research timelines describe.

 Claim Your Bottles